Antibody–Prodrug Conjugates with KSP Inhibitors and Legumain‐Mediated Metabolite Formation

Many antibody–drug conjugates (ADCs) have failed to achieve a sufficient therapeutic window in clinical studies either due to target‐mediated or off‐target toxicities. To achieve an additional safety level, a new class of antibody–prodrug conjugates (APDCs) directed against different targets in soli...

Ausführliche Beschreibung